Logo image of CLPT

CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLPT - US18507C1036 - Common Stock

14.6 USD
+0.2 (+1.39%)
Last: 11/25/2025, 6:34:00 PM
14.8 USD
+0.2 (+1.37%)
After Hours: 11/25/2025, 6:34:00 PM
Fundamental Rating

3

Overall CLPT gets a fundamental rating of 3 out of 10. We evaluated CLPT against 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of CLPT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CLPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLPT has reported negative net income.
CLPT had a negative operating cash flow in the past year.
CLPT had negative earnings in each of the past 5 years.
CLPT had a negative operating cash flow in each of the past 5 years.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

CLPT has a worse Return On Assets (-35.35%) than 60.64% of its industry peers.
With a Return On Equity value of -112.56%, CLPT is not doing good in the industry: 65.96% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -35.35%
ROE -112.56%
ROIC N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CLPT's Gross Margin of 60.42% is fine compared to the rest of the industry. CLPT outperforms 60.11% of its industry peers.
In the last couple of years the Gross Margin of CLPT has declined.
CLPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLPT has been increased compared to 1 year ago.
The number of shares outstanding for CLPT has been increased compared to 5 years ago.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CLPT has an Altman-Z score of 1.67. This is a bad value and indicates that CLPT is not financially healthy and even has some risk of bankruptcy.
CLPT's Altman-Z score of 1.67 is in line compared to the rest of the industry. CLPT outperforms 55.32% of its industry peers.
A Debt/Equity ratio of 1.46 is on the high side and indicates that CLPT has dependencies on debt financing.
The Debt to Equity ratio of CLPT (1.46) is worse than 80.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z 1.67
ROIC/WACCN/A
WACC8.67%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

CLPT has a Current Ratio of 7.30. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.30, CLPT belongs to the top of the industry, outperforming 87.23% of the companies in the same industry.
CLPT has a Quick Ratio of 6.45. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.45, CLPT belongs to the top of the industry, outperforming 88.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.3
Quick Ratio 6.45
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

CLPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.74%.
The Revenue has grown by 31.04% in the past year. This is a very strong growth!
The Revenue has been growing by 22.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%

3.2 Future

Based on estimates for the next years, CLPT will show a small growth in Earnings Per Share. The EPS will grow by 3.12% on average per year.
CLPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.35% yearly.
EPS Next Y-17.3%
EPS Next 2Y0.82%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year18.26%
Revenue Next 2Y21.83%
Revenue Next 3Y32.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 50M 100M 150M 200M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.82%
EPS Next 3Y3.12%

More info and screens

0

5. Dividend

5.1 Amount

CLPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARPOINT NEURO INC

NASDAQ:CLPT (11/25/2025, 6:34:00 PM)

After market: 14.8 +0.2 (+1.37%)

14.6

+0.2 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners39.1%
Inst Owner Change8.51%
Ins Owners5.23%
Ins Owner Change-5.15%
Market Cap434.35M
Revenue(TTM)31.39M
Net Income(TTM)-22.22M
Analysts82.5
Price Target29.58 (102.6%)
Short Float %9.62%
Short Ratio2.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.87%
Min EPS beat(2)-34.8%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-14.9%
Min EPS beat(4)-34.8%
Max EPS beat(4)-1.81%
EPS beat(8)4
Avg EPS beat(8)1%
EPS beat(12)6
Avg EPS beat(12)-2.43%
EPS beat(16)8
Avg EPS beat(16)-1.42%
Revenue beat(2)1
Avg Revenue beat(2)-0.18%
Min Revenue beat(2)-1.8%
Max Revenue beat(2)1.45%
Revenue beat(4)2
Avg Revenue beat(4)-1.35%
Min Revenue beat(4)-7.42%
Max Revenue beat(4)2.36%
Revenue beat(8)5
Avg Revenue beat(8)-0.89%
Revenue beat(12)6
Avg Revenue beat(12)-1.07%
Revenue beat(16)9
Avg Revenue beat(16)0.93%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.93
P/FCF N/A
P/OCF N/A
P/B 22
P/tB 22
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS1.13
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.35%
ROE -112.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.42%
FCFM N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.74%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.3
Quick Ratio 6.45
Altman-Z 1.67
F-Score4
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-17.3%
EPS Next 2Y0.82%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)31.04%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%9.1%
Revenue Next Year18.26%
Revenue Next 2Y21.83%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y-21.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.84%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y38.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.84%
OCF growth 3YN/A
OCF growth 5YN/A

CLEARPOINT NEURO INC / CLPT FAQ

What is the fundamental rating for CLPT stock?

ChartMill assigns a fundamental rating of 3 / 10 to CLPT.


What is the valuation status for CLPT stock?

ChartMill assigns a valuation rating of 0 / 10 to CLEARPOINT NEURO INC (CLPT). This can be considered as Overvalued.


What is the profitability of CLPT stock?

CLEARPOINT NEURO INC (CLPT) has a profitability rating of 1 / 10.


How financially healthy is CLEARPOINT NEURO INC?

The financial health rating of CLEARPOINT NEURO INC (CLPT) is 4 / 10.